|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:approves
|
gptkb:European_Union
gptkb:India
gptkb:United_Kingdom
|
|
gptkbp:clinicalTrials
|
gptkb:Brazil
gptkb:India
gptkb:South_Africa
gptkb:United_Kingdom
Phase III
|
|
gptkbp:contraindication
|
thrombosis
thrombocytopenia
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
gptkb:University_of_Oxford
|
|
gptkbp:distribution
|
gptkb:COVAX_initiative
|
|
gptkbp:drugInterdiction
|
2
|
|
gptkbp:evaluates
|
70.4% average efficacy
|
|
gptkbp:expansion
|
yes
|
|
gptkbp:hasAuthorityOver
|
December 30, 2020
|
|
gptkbp:hasPublications
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Oxford-AstraZeneca COVID-19 vaccine
|
|
gptkbp:name
|
gptkb:Vaxzevria
Covishield
|
|
gptkbp:notable_player
|
viral vector platform
|
|
gptkbp:producedBy
|
gptkb:AstraZeneca
gptkb:SK_Bioscience
gptkb:Serum_Institute_of_India
|
|
gptkbp:providesSupportFor
|
gptkb:New_Zealand_government
gptkb:Vietnam_government
gptkb:Bangladesh_government
gptkb:Costa_Rica_government
gptkb:South_Korea_government
gptkb:COVAX_facility
gptkb:European_Union
gptkb:Paraguay_government
gptkb:UK_government
gptkb:Singapore_government
gptkb:South_Africa_government
gptkb:Venezuela_government
gptkb:Brazil_government
gptkb:India_government
gptkb:Indonesia_government
gptkb:Pakistan_government
gptkb:Philippines_government
gptkb:Thailand_government
various countries
Chile_government
Panama_government
El_Salvador_government
Honduras_government
Uruguay_government
Argentina_government
Australia_government
Bolivia_government
Canada_government
Colombia_government
Ecuador_government
Guatemala_government
Japan_government
Malaysia_government
Nicaragua_government
Peru_government
|
|
gptkbp:sideEffect
|
fatigue
headache
muscle pain
nausea
fever
|
|
gptkbp:storage
|
2 to 8 degrees Celsius
|
|
gptkbp:targets
|
adults
elderly
|
|
gptkbp:technology
|
chimpanzee adenovirus vector
|
|
gptkbp:type
|
viral vector vaccine
|
|
gptkbp:uses
|
prevention of COVID-19
|